Characteristics | All patients (n = 279) | P | One-year survivors (n = 230) | P | ||
---|---|---|---|---|---|---|
MSD-HSCT (N = 182) | HID-HSCT (N = 97) | MSD-HSCT (N = 153) | HID-HSCT (N = 77) | |||
Age | 37.87 (11.59) | 33.07 (12.32) | 0.00b | 37.71 (11.438) | 34.25 (11.703) | 0.03b |
Gender Male | 90 (49.45) | 51 (52.58) | 0.71 | 77 (50.33) | 38 (49.35) | 1.00 |
 BMI ≥ 25 | 58 (31.87) | 29 (29.90) | 0.79 | 46 (30.07) | 25 (32.47) | 0.76 |
 Education (years) |  |  | 0.42 |  |  | 0.67 |
  < 6 | 5 (2.75) | 6 (6.19) |  | 5 (3.27) | 4 (5.19) |  |
 6 ~ 12 | 124 (68.13) | 60 (61.86) |  | 102 (66.67) | 48 (62.34) |  |
  > 12 | 53 (29.12) | 32 (32.99) |  | 46 (30.07) | 25 (32.47) |  |
Marital status | Â | Â | 0.02b | Â | Â | 0.08 |
 Single | 39 (21.43) | 35 (36.08) |  | 31 (20.26) | 26 (33.77) |  |
 Married | 141 (77.47) | 60 (61.86) |  | 120 (78.43) | 50 (64.94) |  |
 Divorced/widowed | 2 (1.10) | 2 (2.06) |  | 2 (1.31) | 1 (1.29) |  |
Main caregivers | Â | Â | 0.02b | Â | Â | 0.03b |
 Spouse | 74 (40.66) | 53 (54.64) |  | 59 (38.56) | 42 (54.55) |  |
 Alternative | 109 (59.89) | 44 (45.36) |  | 94 (61.44) | 35 (45.45) |  |
Family income (rmb/year) | Â | Â | 0.15 | Â | Â | 0.08 |
  < 100000 | 81 (44.51) | 33 (34.02) |  | 69 (45.10) | 24 (31.17) |  |
  ≥ 100000 | 94 (51.65) | 57 (58.76) |  | 79 (51.63) | 48 (62.34) |  |
Source of medical payment | Â | Â | 0.36 | Â | Â | 0.89 |
 Insurance | 111 (60.99) | 64 (65.98) |  | 96 (62.75) | 49 (63.63) |  |
 Self-payment | 70 (38.46) | 31 (31.96) |  | 56 (36.60) | 27 (35.06) |  |
Diagnosis | Â | Â | 0.01b | Â | Â | 0.09 |
 AML/ALL | 117 (64.29) | 79 (81.44) |  | 98 (64.05) | 61 (79.22) |  |
 MDS/MPN | 48 (26.37) | 16 (16.49) |  | 42 (27.45) | 14 (18.18) |  |
 AA | 15 (8.24) | 2 (1.10) |  | 11 (7.19) | 2 (2.60) |  |
 Lymphoma | 2 (1.10) | 0 |  | 2 (1.31) | 0 |  |
Cytogenetic Data | Â | Â | 0.57 | Â | Â | 0.29 |
 Normal | 121 (66.48) | 68 (70.10) |  | 102 (66.67) | 58 (75.32) |  |
 Monosomal karyotype | 32 (17.58) | 11 (11.34) |  | 29 (18.95) | 7 (9.09) |  |
 Complex karyotype | 18 (9.89) | 12 (12.37) |  | 14 (9.15) | 8 (10.39) |  |
 Unable to define the karyotype | 11 (6.04) | 6 (6.19) |  | 8 (5.23) | 4 (5.19) |  |
Hematologic Response at HSCT | Â | Â | 1.00 | Â | Â | 0.88 |
 CR | 130 (71.43) | 69 (71.13) |  | 110 (71.90) | 54 (70.13) |  |
 Non-CR or untreated | 52 (28.57) | 28 (28.87) |  | 43 (28.10) | 23 (29.87) |  |
ECOG Performance Score | Â | Â | 0.89 | Â | Â | 0.31 |
 0 (fully active) | 121 (66.48) | 66 (68.04) |  | 95 (62.09) | 54 (70.13) |  |
  > 0 | 61 (33.52) | 31 (31.96) |  | 58 (37.91) | 23 (29.87) |  |
HCT-CI | Â | Â | 0.49 | Â | Â | Â 0.17 |
 0 ~ 1 | 172 (94.50) | 89 (91.75) |  | 145 (94.77) | 70 (90.91) |  |
 2 | 10 (5.49) | 8 (8.25) |  | 8 (5.23) | 7 (9.09) |  |
GVHD prophylaxis | Â | Â | 0.18 | Â | Â | 0.16 |
 CSA-based | 156 (85.71) | 77 (79.38) |  | 135 (88.24) | 62 (80.52) |  |
 FK506-based | 26 (14.29) | 20 (20.62) |  | 18 (11.76) | 15 (19.48) |  |
 Use of ATG | 75(41.21) | 97(100) | 0.00b | 63(41.18) | 77(100) | 0.00b |
Blood type | Â | Â | 0.80 | Â | Â | 0.78 |
 Match | 75 (41.21) | 37 (38.14) |  | 63 (41.18) | 30 (38.96) |  |
 Mismatch | 108 (59.34) | 59 (60.82) |  | 90 (58.82) | 47 (61.04) |  |
 Neutrophil engraftment | 14.62 (15.10) | 18.15 (24.17) | 0.31 | 14.96 (16.422) | 15.11 (3.272) | 0.94 |
 Platelet engraftment | 16.34 (13.19) | 17.86 (8.45) |  | 16.8 (14.295) | 19 (8.785) | 0.22 |
Infection | ||||||
 Bacteria | 69 (37.91) | 34 (35.05) | 0.70 | 74 (48.37) | 28 (36.36) | 0.08 |
 Fungus | 34 (18.68) | 30 (30.93) | 0.02b | 18 (11.76) | 7 (10.87) | 0.54 |
 CMV | 55 (30.22) | 41 (42.27) | 0.04b | 33 (21.57) | 26 (33.77) | 0.04b |
 aGVHD | 64 (35.16) | 53 (54.64) | 0.00b | 52 (33.99) | 44 (57.14) | 0.00b |
 cGVHD | 26 (14.29) | 11 (11.34) | 0.58 | 26 (16.99) | 10 (12.99) | 0.43 |